EP1212355A2 - Pharmaceutical compositions and methods of using secreted frizzled related protein - Google Patents

Pharmaceutical compositions and methods of using secreted frizzled related protein

Info

Publication number
EP1212355A2
EP1212355A2 EP00960097A EP00960097A EP1212355A2 EP 1212355 A2 EP1212355 A2 EP 1212355A2 EP 00960097 A EP00960097 A EP 00960097A EP 00960097 A EP00960097 A EP 00960097A EP 1212355 A2 EP1212355 A2 EP 1212355A2
Authority
EP
European Patent Office
Prior art keywords
sfrp
hob
cells
bone
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00960097A
Other languages
German (de)
English (en)
French (fr)
Inventor
Peter V. N. Bodine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1212355A2 publication Critical patent/EP1212355A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to compositions and methods for regulating bone-forming activity. More particularly, the present invention relates to methods and pharmaceutical compositions for regulating bone forming activity with a secreted frizzled related protein (SFRP) derived form an osteoblast cell line, portions thereof, as well as antibodies and nucleic acids, including antisense, based thereon.
  • SFRP frizzled related protein
  • Wnt proteins are a family of growth factors consisting of more than a dozen structurally related molecules and are involved in the regulation of fundamental biological processes like apoptosis, embryogenesis, organogenesis, morphogenesis and tumorigenesis (reviewed in Nusse and Varmus 1 992 Cell 69: 1073-1087). These polypeptides are multipotent factors and have similar biological activities to other secretory proteins like transforming growth factor (TGF)- ⁇ , fibroblast growth factors (FGFs), nerve growth factor (NGF) and bone morphogenetic proteins (BMPs).
  • TGF transforming growth factor
  • FGFs fibroblast growth factors
  • NGF nerve growth factor
  • BMPs bone morphogenetic proteins
  • Wnt-x One member of the Wnt growth factor family termed Wnt-x, is preferentially expressed in bone tissue and in bone-derived cells and appears to be involved in maintaining the mature osteoblast (bone-forming cell) phenotype (PCT/US94/14708; WO 95/1741 6).
  • Wnt-x One member of the Wnt growth factor family termed Wnt-x, is preferentially expressed in bone tissue and in bone-derived cells and appears to be involved in maintaining the mature osteoblast (bone-forming cell) phenotype (PCT/US94/14708; WO 95/1741 6).
  • Frizzled proteins contain an amino terminal signal sequence for secretion, a cysteine-rich domain (CRD) that is thought to bind Wnt, seven putative transmembrane domains that resemble a G-protein coupled receptor, and a cytoplasmic carboxyl terminus.
  • CCD cysteine-rich domain
  • compositions for regulating bone-forming activity in a mammal comprising a secreted frizzled related protein (SFRP) or regulating portion thereof.
  • Additional compositions of the present invention employ antibodies formed from such proteins or portions thereof, and alternatively can employ nucleic acids that encode such proteins or portions thereof, including antisense sequences.
  • the SFRP is from human osteoblast cells.
  • the bone forming activities regulated by the composition of the present invention include the regulation of bone growth and bone density.
  • the SFRP has the amino acid sequence set forth in SEQ ID NO: 2 which is obtained by the expression of the polynucleotide sequence set forth in SEQ ID NO 1 .
  • the SFRP is SFRP-1 (SEQ ID NO 2).
  • methods of the present invention include methods for treating a bone disorder in a mammal, particularly a human comprising the steps of administering a pharmaceutical composition described above.
  • the methods for treating a bone disorder include but are not limited to disorders comprising the group consisting of (a) a bone formation disorder, (b) a bone resorption disorder and (c) a bone density disorder.
  • the bone disorder is a degenerative bone disorder wherein the degenerative bone disorder is selected from the group consisting of neurodegeneration, myodegeneration, and osteodegeneration disorders.
  • the osteodegeneration disorder is selected from the group consisting of osteopenia, osteoarthritis, osteoporosis.
  • the invention includes methods for identifying test compounds regulating SFRP activity.
  • the compounds regulating the bone-forming activity in a mammal are assayed by first incubating a sample comprising a SFRP in a test medium containing the test compound. The next step is to determine the SFRP activity, wherein an increase in activity relative to SFRP alone indicates the compound is a SFRP activator and a decrease in activity indicates the compound is a SFRP inhibitor.
  • the invention includes methods of modulating Wnt-mediated signaling in a cell comprising contacting said cell with the SFRP described above, wherein said Wnt activity is regulated.
  • the present invention additionally relates to a method of facilitating bone formation or repair in a bone cell culture, comprising isolating the cells from a bone culture, introducing a recombinant construct expressing SFRP having the amino acid sequence set forth in SEQ ID NO: 2, and returning said cells into the bone culture.
  • the construct expresses an antisense sequence for a nucleic acid sequence which encodes all or a portion of a SFRP protein.
  • Another embodiment relates to a polynucleotide probe capable of hybridizing with the polynucleotide having the nucleic acid sequence set forth in SEQ ID NO: 1 . Such probe is used in a diagnostic process for detecting a SFRP polynucleotide in a sample derived from a mammalian host comprising detecting the presence or absence of the SFRP in the sample.
  • Figure 1 shows the osteogenic RADE results that lead to the discovery of the human osteoblast (hOB) secreted frizzled-related protein (SFRP) cDNA.
  • the figure shows autoradiograms of differential-display polymerase chain reaction (DD-PCR) gels from the experiments performed with the three hOB cell lines (hOB-03-C5, hOB-03-CE6 and hOB-01 -C1 ) in three different stages of differentiation (proliferative-stage, maturation-stage and pre-osteocytic).
  • DD-PCR differential-display polymerase chain reaction
  • the arrow points to the 276 base pair (bp) hOB SFRP gene fragment (i.e., RADE fragment) that is up-regulated by PGE 2 treatment in the hOB-03-C5 and hOB-03-CE6 cells, but is down-regulated by TGF- ⁇ 1 treatment in the hOB-01 -C1 cells. It can also be seen that the hOB-01 -C1 cells express high basal levels of this gene. A basic local alignment search tool (BLAST) search of this gene fragment against the public databases indicated that this cDNA was homologous to the mouse SFRP-1 and bovine FrzA genes.
  • BLAST basic local alignment search of this gene fragment against the public databases indicated that this cDNA was homologous to the mouse SFRP-1 and bovine FrzA genes.
  • Figure 2 shows an autoradiogram of a Northern blot of poly A + RNA isolated from the hOB-03-C5 cells after treatment with control, PTH, PGE 2 and TGF- ⁇ 1 for 24 hr.
  • both the excised hOB SFRP RADE gene fragment and a cloned glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA were used as probes.
  • the arrow points to the hOB SFRP mRNA ( — 4.4 kb) which is completely up-regulated by treatment of the cells with PGE 2 .
  • Figure 3 shows an autoradiogram of a Northern blot of poly A + RNA isolated from the hOB-03-C5 cells after treatment with control, PGE 2 and TGF- ⁇ 1 for 24 hr.
  • both the cloned hOB SFRP RADE gene fragment and a cloned GAPDH cDNA were used as probes.
  • the hOB SFRP mRNA is completely up-regulated by treatment of the cells with PGE 2 .
  • Figure 4 shows an autoradiogram of a Northern blot of poly A + RNA isolated from either the hOB-03-CE6 or hOB-01 -C1 cells after treatment with control, PTH, PGE 2 and TGF- ⁇ 1 for 24 hr.
  • both the excised hOB SFRP RADE gene fragment and a cloned GAPDH cDNA were used as probes.
  • the arrow points to the hOB SFRP mRNA that is completely up-regulated by treatment of the hOB-03-CE6 cells with PGE 2 , but is down- regulated by treatment of the hOB-01 -C1 cells with PTH. It can also be seen that the hOB-01 -C1 cells express high basal levels of the mRNA.
  • Figure 5 shows an autoradiogram of a Northern blot of poly A + RNA isolated from the hOB-01 -C1 cells after treatment with control and TGF- ⁇ 1 for 24 hr.
  • both the full-length (1 .1 kb) cloned hOB SFRP cDNA and a cloned beta-Actin cDNA were used as probes.
  • the results show that the hOB SFRP mRNA is down-regulated by treatment of the cells with TGF- ⁇ 1 .
  • the hOB-01 -C1 cells express high basal levels of the mRNA.
  • Figure 6 shows an autoradiogram of a Northern blot of poly A + RNA isolated from 23 different human tissues.
  • both the excised hOB SFRP RADE gene fragment and a cloned beta-Actin cDNA were used as probes.
  • the arrow points to the hOB SFRP mRNA that is highly expressed in heart and kidney, moderately expressed in placenta and uterus, expressed at lower levels in brain, pancreas and other tissues, but not expressed in thymus and lymphocytes.
  • Figure 7 shows an autoradiogram of a Northern blot of poly A + RNA isolated from SaOS-2 human osteosarcoma osteoblast-like cells and explant cultures of normal human osteoblasts (hOB) after treatment with control, PTH, PGE 2 and TGF- ⁇ 1 for 24 hr.
  • hOB normal human osteoblasts
  • both the full-length cloned hOB SFRP cDNA and a cloned GAPDH cDNA were used as probes.
  • the results show that the SaOS-2 cells express low basal levels of hOB SFRP mRNA which is not regulated by these agents.
  • hOB cells express moderate levels of this message which is up-regulated by treatment with PGE 2 .
  • TaqMan quantitative RT-PCR analysis of hOB cells treated with PGE 2 indicated that PGE 2 upregulated SFRP message levels 10-fold.
  • Figure 8 shows an autoradiogram of a Southern blot of reverse transcriptase (RT)-PCR products of total RNA isolated from either human placenta or hOB-03-CE6 cells after treatment with control or PGE 2 for 24 hr.
  • RT-PCR was performed with oligonucleotide primers that were specific for human FRP-1 /SARP-2, and the Southern blot was hybridized with an internal oligonucleotide probe specific for human FRP-1 /SARP-2.
  • the expected size for this RT-PCR product was 1 .1 kb.
  • the results shown that (as expected) placenta expresses FRP-1 /SARP-2 mRNA, and that PGE 2 treatment of the hOB-03-CE6 cells strongly upregulates the expression of this message.
  • Figure 9 shows the results of a cell viability experiment with the hOB- 03-C5, hOB-03-CE6 and hOB-01 -C1 cells using the Coulter cell counter. The results are presented as the % relative to the day 0 control (i.e., - 200,000 cells per well of a 6 well plate). The results of this experiment indicate that the hOB-03-C5 cells proliferate slowly at 39°C in serum-containing medium, while the hOB-03-CE6 cells stop dividing but are viable for the 6 day incubation. In contrast, the hOB-01 -C1 cells undergo accelerated cell death, which correlates with the high basal expression of hOB SFRP mRNA in these cells.
  • Figure 10 shows the results of a cell viability experiment with the hOB-03-C5 cells (panel A), hOB-03-CE6 cells (panel B) and hOB-01 -C1 cells (panel C) using the Coulter cell counter.
  • the cells were treated with either control or PGE 2 (panels A & B) or control and TGF- ⁇ l (panel C) in serum-free medium at 39°C for 3 or 6 days.
  • the results are presented as the % relative to the day 0 control (i.e., - 200,000 cells per well of a 6 well plate). The results of this experiment indicate that hOB cell viability declines over time in serum-free medium.
  • Panel A shows that the number of viable cells, which do not stain with either annexin V or propidium iodide (a stain for necrotic cells), declines with increasing PGE 2 concentrations.
  • panel B shows that the number of apoptotic cells, which stain with annexin V but not propidium iodide, increases with increasing PGE 2 concentrations.
  • panel C shows that the number of necrotic cells, which stain with both annexin V and propidium iodide, increases with increasing PGE 2 concentrations.
  • Figure 1 2 shows the results of another cell viability experiment with the hOB-03-C5 cells (panel A) and hOB-03-CE6 cells (panel B) using the Coulter cell counter.
  • vehicle control i.e., 0.1 % ethanol
  • PGE 2 in the absence or presence of sense (control) or antisense initiation-site directed phosphorothioate oligonucleotides to human SARP-2.
  • the results are presented as either the % relative to the day 0 control (i.e., — 200,000 cells per well of a 6 well plate) or as the % relative to the vehicle treated control.
  • Figure 13 shows the results of a cell viability experiment with the hOB-01 -C1 -PS-09 cells using the Coulter cell counter (panel A).
  • the cells were stably transfected with either an hOB SFRP cDNA (i.e., SFRP-1 /FRP-1 /SARP-2) mammalian expression plasmid or the empty vector (i.e., pcDNA3.1 ).
  • the results are presented as the % of the day 0 control cells.
  • the results of this experiment indicates that overexpression of hOB SFRP/SFRP-1 /FRP-1 /SARP-2 by the hOB cells accelerates the rate of cell death when compared to the empty vector which has no effect on this process.
  • Panel B shows the results of a Northern hybridization of poly A + RNA isolated from either the empty vector cells (V) or the SARP-2 overexpressing cells (S). This analysis demonstrates that the SARP-2 cells express substantially more SFRP-1 /FRP-1 /SARP-2 mRNA than the vector cells.
  • Figure 14 shows the results of another cell viability experiment performed with the empty vector expressing hOB-01 -C1 -PS-09 cells (pcDNA3.1 ) and a subclone of the SFRP-1 /FRP-1 /SARP-2 overexpressing cells (SARP-2 Clone #1 ).
  • Panel A shows the results of a TaqMan quantitative RT-PCR analysis of RNA isolated from the cells. This analysis indicates that the SARP-2 Clone #1 cells express 50-60 times more human SFRP-1 /FRP-1 /SARP-2 mRNA than the empty vector expressing cells.
  • the SARP-2 Clone #1 cells die at a rate that is 3-times faster than the empty vector control cells using the Coulter cell counter to measure cell number.
  • Figure 1 5 is an autoradiogram of a Western blot of whole cell extracts isolated from hOB-03-CE6 cells treated with either control or PGE 2 for 24 hr.
  • the immunoblot was probed with a monoclonal antibody to ⁇ -catenin, which has a molecular weight of 92,000.
  • the results show that treatment of the hOB cells with PGE 2 downregulates ⁇ -catenin levels, which is consistent with an antagonism of the Wnt signaling pathway by hOB SFRP/SFRP-1 /FRP- 1 /SARP-2.
  • Figure 1 6 shows the results of a transient transfection experiment with the hOB-01 -C1 -PS-09 cells (panel A) and hOB-02-C1 -PS-02 cells (panel B).
  • the results show that transfection of either human [h] or rat [r] SARP-2 or human Frzb-1 expression plasmids downregulates Wnt signaling (when compared to the pcDNA3.1 empty vector control) in the hOB cells as measured by the TCF-luciferase reporter gene assay.
  • This assay is an authentic measurement of Wnt signaling and ⁇ -catenin nuclear activity.
  • FIG 17 summarizes a screening paradigm for anabolic bone agents using the hOB cells and hOB SFRP/SFRP-1 /FRP-1 /SARP-2.
  • This screening paradigm would identify compounds that regulate SFRP-1 /FRP-1 /SARP-2 function.
  • Figure 18 depicts an example of a high-throughput screening (HTS) assay for compounds that inhibit SFRP-1 /FRP-1 /SARP-2 function in osteoblastic/osteocytic cells.
  • HTS high-throughput screening
  • Figure 1 9 outlines the strategy that was used to create the SFRP- 1 /SARP-2 knock-out mice.
  • Exon 1 of the mouse SFRP-1 /SARP-2 gene. which encodes for the entire cysteine-rich domain (CRD) was replaced with the expression cassette for ⁇ -galactosidase and neomycin resistance.
  • Figure 20 depicts a Northern blot of poly A + RNA isolated from female and male kidneys obtained from the wild-type (WT) and knock-out (KO) SFRP-1 mice. This blot shows that the WT kidneys express high levels of SFRP-1 mRNA (4.4 kb), while the KO kidneys do not express this gene.
  • WT wild-type
  • KO knock-out
  • Figure 21 shows the results of a micro-computerized tomography (micro-CT) analysis of femurs obtained from the male (panel A) and female (panel B) wild-type ( + / + ) and knock-out (-/-) SFRP-1 mice.
  • micro-CT micro-computerized tomography
  • the data demonstrate that the -/- mice exhibit increased parameters of bone formation (i.e., BV/TV, Tb. Th., Conn. Den., Tb. N. & Tb. Sp.) as determined by this method.
  • Figure 22 is a set of graphs showing (A) cell proliferation of hOB cells (B) the ability/enhancement in hOB cells for vitamin D 3 - treatment to up-
  • vitamin D 3 to induce osteocalcin secretion from hOB cells at 34° C, as detailed in Example A.
  • Figure 23 depicts the results from Example A regarding the expression of PTH-1 receptor mRNA expression; wherein incubation of the
  • hOB cells ells for 48 hours at 39° C increases the steady-state message levels for PTH-1 receptor by 7-fold when compared to cells maintained at
  • Figure 24 depicts the results from Example A for the effect on intracellular cyclic adenosine monohosphate (cAMP) in response to increasing concentrations of PTH 1 -34 in the hOB cells.
  • cAMP cyclic adenosine monohosphate
  • Figure 25 is a graph which depicts the effect of hOB cells when treated with synthetic glucorticoid dexamethasone, which up-regulates alkaline phosphatase activity, as detailed in Example A.
  • Figure 26 depicts the results from experiments on the effect of mechanosensory stimulation on pre-osteocytic hOB cells, when subject to a Flexerall Strain Unit.
  • the present invention relates to a gene whose expression is regulated by osteogenic or bone-forming agents in three different human osteoblast
  • hOB hOB cell lines in vitro.
  • the expression of this gene is upregulated during hOB differentiation, suggesting it may be involved in the bone formation process.
  • DNA sequence analysis indicated that this gene fragment shared significant sequence identity to a mouse cDNA called secreted frizzled-related protein (SFRP)-1 (Rattner et al.
  • SFRP contemplates its use as a novel osteoporotic drug target and in a novel drug screen for identifying anabolic bone agents.
  • bone formation is the process of bone synthesis and mineralization.
  • the osteoblast cell modulates the process.
  • bone growth is the process of skeletal expansion. This process occurs by one of two ways: ( 1 ) intramembraneous bone formation arises directly from mesenchymal or bone marrow cells; (2) longitudinal or endichindual bone formation arises where bone from cartilage.
  • osteogenesis is synonymous with the term bone formation, defined above.
  • secreted frizzled related proteins or "SFRP” is a secreted receptor of the Wnt signaling pathway and exhibits a number of characteristics that make it a useful tool for studying cell growth and differentiation.
  • the frizzled like gene family encodes cell membrane proteins having transmembrane domains with unknown functions.
  • secreted apoptosis related protein or "SARP” are synonymous with the term secreted frizzled related proteins or SFRPs defined above.
  • proteins proteins
  • peptides and “polypeptides” are used interchangeably and are intended to include purified and recombinantly produced SFRP molecules containing amino acids linearly coupled through peptide bonds.
  • the amino acids of this invention can be in the L or D form so long as the biological activity of the polypeptide is maintained.
  • the SFRP proteins of this invention may also include proteins that are post- translationally modified by reactions that include glycosylation, acetylation and phosphorylation.
  • Such polypeptides also include analogs, alleles and allelic variants that can contain amino acid derivatives or non-amino acid moieties that do not affect the biological or functional activity of the SFRP protein as compared to wild-type or naturally occurring protein.
  • amino acid refers both to the naturally occurring amino acids and their derivatives, such as TyrMe and PheCI, as well as other moieties characterized by the presence of both an available carboxyl group and an amine group.
  • Non-amino acid moieties that can be contained in such polypeptides include, for example, amino acid mimicking structures. Mimicking structures are those structures that exhibit substantially the same spatial arrangement of functional groups as amino acids but do not necessarily have both the amino and carboxyl groups characteristic of amino acids.
  • “Muteins” are SFRP proteins or polypeptides that have minor changes in amino acid sequence caused, for example, by site-specific mutagenesis or other manipulations; by errors in transcription or translation; or which are prepared synthetically by rational design. These minor alterations result in amino acid sequences wherein the biological activity of the protein or polypeptide is altered as compared to wild-type or naturally occurring polypeptide or protein. Examples of muteins include the SFRP-1 of SEQ. ID. No. 2 described herein.
  • hydrophobic is intended to include those amino acids, amino acid derivatives, amino acid mimics and chemical moieties that are non-polar. Hydrophobic amino acids include Phe, Val, Trp, lie, and Leu.
  • positively charged amino acid refers to those amino acids, amino acid derivatives, amino acid mimics and chemical moieties that are positively charged. Positively charged amino acids include, for example, Lys, Arg and His.
  • SFRP protein or polypeptide when referring to a SFRP protein or polypeptide, is distinguishable from native or naturally occurring proteins or polypeptides because they exist in a purified state.
  • purified SFRP proteins or polypeptides or any of the intended variations as described herein, shall mean that the compound or molecule is substantially free of contaminants normally associated with the compound in its native or natural environment.
  • substantially pure and isolated are not intended to exclude mixtures of polynucleotides or polypeptides with substances that are not associated with the polynucleotides or polypeptides in nature.
  • “Native” SFRP polypeptides, proteins, or nucleic acid molecules refer to those SFRP recovered from a source occurring in nature or "wild-type”.
  • composition is intended to mean a combination of active agent, i.e., the SFRP of the present invention and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.
  • a "pharmaceutical composition” is intended to include the combination of SFRP, particularly SFRP-1 as the active agent with a carrier, inert or active, making the composition suitable for diagnostic or therapeutic use in vitro, in vivo or ex vivo.
  • the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives.
  • stabilizers and adjuvants see Martin, Remington's Pharm. Sci., 1 5th Ed. (Mack Publ. Co.. Easton (1 975)).
  • nucleic acid as it relates to the SFRP described herein means single and double stranded DNA, cDNA, genome-derived DNA, and RNA, as well as the positive and negative strand of the nucleic acid that are complements of each other, including anti-sense RNA.
  • a "nucleic acid molecule” is a term used interchangeably with “polynucleotide” and each refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, or analogs thereof. It also includes known types of modifications, for example labels which are known in the art (e.g., Sambrook et al.
  • nucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl carbamate, etc.), those containing pendant moieties, such as for example, proteins (including, e.g., nuclease, toxins, antibodies, signal peptides, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide.
  • uncharged linkages e.g., methyl carbamate, etc.
  • pendant moieties such as for example, proteins (including, e.g., nuclease, toxins, antibodies, signal peptides, etc.), those with intercalators (e
  • the polynucleotide can be chemically or biochemically modified or contain non-natural or derivatized nucleotide bases.
  • the nucleotides may be complementary to the mRNA encoding the polypeptides. These complementary nucleotides include, but are not limited to, nucleotides capable of forming triple helices and antisense nucleotides.
  • Recombinant polynucleotides comprising sequences otherwise not naturally occurring are also provided by this invention, as are alterations of wild-type polypeptide sequences, including but not limited to, those due to deletion, insertion, substitution of one or more nucleotides or by fusion to other polynucleotide sequences.
  • a SFRP polynucleotide is said to "encode" a SFRP polypeptide if, in its native state or when manipulated by methods well-known to those skilled in the art, it can be transcribed and/or translated to produce a polypeptide or mature protein.
  • the term polynucleotide shall include, in addition to coding sequences, processing sequences and other sequences that do not code for amino acids of the mature protein.
  • the anti-sense strand of such a polynucleotide is also said to encode the sequence.
  • polynucleotide or DNA refers to a polynucleotide that is made by the combination of two otherwise separated segments of sequence accomplished by the artificial manipulation of isolated segments of DNA by genetic engineering techniques or by chemical synthesis. In so doing, one may join together DNA segments of desired functions to generate a desired combination of functions.
  • an "analog" of a SFRP DNA, RNA or a polynucleotide refers to a macromolecule resembling naturally occurring polynucleotides in form and/or function (particularly in the ability to engage in sequence-specific hydrogen bonding to base pairs on a complementary polynucleotide sequence) but which differs from DNA or RNA in, for example, the possession of an unusual or non-natural base or an altered backbone. See for example, Uhlmann et al. ( 1 990) Chemical Reviews 90:543-584. "Isolated when referring to a SFRP nucleic acid molecule, means separated from other cellular components normally associated with native or wild-type SFRP DNA or RNA intracellularly.
  • Hybridization refers to hybridization reactions that can be performed under conditions of different “stringency” . Conditions that increase the stringency of a hybridization reaction are widely known and published in the art: see, for example, Sambrook et al., infra.
  • Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25 °C, 37°C, 50°C, and 68°C; buffer concentrations of 10 x SSC, 6 x SSC, 1 X SSC, 0.1 x SSC (where SSC is 0.1 5 M NaCI and 1 5 mM citrate buffer) and their equivalent using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%, incubation times from 5 minutes to 24 hours and washes of increasing duration, increasing frequency, or decreasing buffer concentrations.
  • T m is the temperature in degrees Centigrade at which 50% of a polynucleotide duplex made of complementary strands hydrogen bonded in an antiparallel direction by Watson-Crick base paring dissociates into single strands under the conditions of the experiment.
  • a "stable duplex" of polynucleotides, or a “stable complex” formed between any two or more components in a biochemical reaction refers to a duplex or complex that is sufficiently long lasting to persist between the formation of the duplex or complex, and its subsequent detection.
  • duplex or complex must be able to withstand whatever conditions exist or are introduced between the moment of formation and the moment of detection, these conditions being a function of the assay or reaction which is being performed.
  • Intervening conditions which may optionally be present and which may dislodge a duplex or complex include washing, heating, adding additional solutes or solvents to the reaction mixture (such as denaturants), and competing with additional reacting species.
  • Stable duplexes or complexes may be irreversible or reversible, but must meet the other requirements of this definition.
  • a transient complex may form in a reaction mixture, but it does not constitute a stable complex if it dissociates spontaneously or as a result of a newly imposed condition or manipulation introduced before detection.
  • a double-stranded polynucleotide can be "complementary" to another polynucleotide, if a stable duplex can form between one of the strands of the first polynucleotide and the second.
  • a complementary sequence predicted from the sequence of single stranded polynucleotide is the optimum sequence of standard nucleotides expected to form hydrogen bonding with the single-stranded polynucleotide according to generally accepted base-pairing rules.
  • a “sense” strand and an “antisense” strand when used in the same context refer to single-stranded SFRP polynucleotides which are complementary to each other. They may be opposing strands of a double- stranded polynucleotide, or one strand may be predicted from the other according to generally accepted base-pairing rules. Unless otherwise specified or implied, the assignment of one or the other strand as “sense” or “antisense” is arbitrary.
  • a linear sequence of SFRP nucleotides is "identical" to another linear sequence, if the order of nucleotides in each sequence is the same, and occurs without substitution, deletion, or material substitution. It is understood that purine and pyrimidine nitrogenous bases with similar structures can be functionally equivalent in terms of Watson-Crick base- pairing; and the inter-substitution of like nitrogenous bases, particularly uracil and thymine, or the modification of nitrogenous bases, such as by methylation, does not constitute a material substitution.
  • RNA and a DNA polynucleotide have identical sequences when the sequence for the RNA reflects the order of nitrogenous bases in the polyribonucleotide, the sequence for the DNA reflects the order of nitrogenous bases in the polydeoxyribonucleotide, and the two sequences satisfy the other requirements of this definition.
  • the sequences are a degenerate oligonucleotide comprising an ambiguous residue, the two sequences are identical if at least one of the alternative forms of the degenerate oligonucleotide is identical to the sequence with which it is being compared.
  • AYAAA (SEQ ID NO 3) is identical to ATAAA (SEQ ID NO 4), if AYAAA (SEQ ID NO 5) is a mixture of ATAAA (SEQ ID N06 ) and ACAAA (SEQ ID NO 7).
  • a linear sequence of nucleotides is "essentially identical” or the "equivalent” to another linear sequence, if both sequences are capable of hybridizing to form duplexes with the same complementary polynucleotide. It should be understood, although not always explicitly stated that Applicants refer to a specific nucleic acid molecule, its equivalents are also intended. Sequences that hybridize under conditions of greater stringency are more preferred. It is understood that hybridization reactions can accommodate insertions, deletions, and substitutions in the nucleotide sequence. Thus, linear sequences of nucleotides can be essentially identical even if some of the nucleotide residues do not precisely correspond or align. Sequences that correspond or align more closely to the invention disclosed herein are comparably more preferred.
  • a polynucleotide region of about 25 residues is essentially identical to another region, if the sequences are at least about 80% identical; more preferably, they are at least about 90% identical; more preferably, they are at least about 95% identical; still more preferably, the sequences are 100% identical.
  • a polynucleotide region of 40 residues or more will be essentially identical to another region, after alignment of homologous portions if the sequences are at least about 75% identical; more preferably, they are at least about 80% identical; more preferably, they are at least about 85% identical; even more preferably, they are at least about 90% identical; still more preferably, the sequences are 100% identical.
  • a sequence that preserves the functionality of the polynucleotide with which it is being compared is particularly preferred. Functionality can be determined by different parameters. For example, if the polynucleotide is to be used in reactions that involve hybridizing with another polynucleotide, then preferred sequences are those which hybridize tot he same target under similar conditions.
  • the T m of a DNA duplex decreases by about 10°C for every 1 % decrease in sequence identity for duplexes of 200 or more residues; or by about 50°C for duplexes of less than 40 residues, depending on the position of the mismatched residues (see, e.g.
  • Essentially identical or equivalent sequences of about 100 residues will generally form a stable duplex with each other's respective complementary sequence at about 20°C less than T m ; preferably, they will form a stable duplex at about 1 5 °C less; more preferably, they will form a stable duplex at about 10°C less; even more preferably, they will form a stable duplex at about 5°C less; still more preferably, they will form a stable duplex at about T m .
  • preferred sequences are those which encode identical or essentially identical polypeptides.
  • nucleotide differences which cause a conservative amino acid substitution are preferred over those which can cause a non-conservative amino acid substitution are preferred over those which cause a non-conservative substitution, nucleotide differences which do not alter the amino acid sequence are more preferred, while identical nucleotides are even more preferred.
  • Insertions or deletions in the polynucleotide that result in insertions or deletions in the polypeptide are preferred over those that result in the down-stream coding regions being rendered out of phase; polynucleotide sequences comprising no insertions or deletions are even more preferred.
  • the relative importance of hybridization properties and the encoded polypeptide sequence of a polynucleotide depends on the application of the invention.
  • a polynucleotide has the same characteristics or is the equivalent of another polynucleotide if both are capable of forming a stable duplex with a particular third polynucleotide under similar conditions of maximal stringency.
  • the polynucleotides also encode essentially identical polypeptides.
  • Constant residues of a polynucleotide sequence are those residues that occur unaltered in the same position of two or more related sequences being compared. Residues that are relatively conserved are those that are conserved amongst more related sequences than residues appearing elsewhere in the sequences. "Related" polynucleotides that share a significant proportion of identical residues.
  • a "degenerate" oligonucleotide sequence is a designed sequence derived from at least two related originating polynucleotide sequences as follows: the residues that are conserved in the originating sequences are preserved in the degenerate sequence, while residues that are not conserved in the originating sequences may be provided as several alternatives in the degenerate sequence.
  • the degenerate sequence AYASA (SEQ ID NO 8)may be assigned from originating sequences ATACA (SEQ ID NO 9) and ACAGA (SEQ ID NO 10), where Y is C or T and S is C or G. Y and S are examples of "ambiguous" residues.
  • a degenerate segment is a segment of a polynucleotide containing a degenerate sequence.
  • a synthetic oligonucleotide comprising a degenerate sequence is actually a mixture of closely related oligonucleotides sharing an identical sequence, except at the ambiguous positions.
  • Such an oligonucleotide is usually synthesized as a mixture of all possible combinations of nucleotides at the ambiguous positions.
  • Each of the oligonucleotides in the mixture is referred to as an "alternative form".
  • a polynucleotide "fragment” or "insert” as used herein generally represents a sub-region of the full-length form, but the entire full-length polynucleotide may also be included.
  • RNA corresponds to the gene from which it is transcribed.
  • cDNA corresponds to the RNA from which it has been produced, such as by a reverse transcription reaction, or by chemical synthesis of a DNA based upon knowledge of the RNA sequence.
  • cDNA also corresponds to the gene that encodes the RNA.
  • Polynucleotides also "correspond" to each other if they serve a similar function, such as encoding a related polypeptide, in different species, strains or variants that are being compared.
  • a "probe” when used in the context of SFRP polynucleotide manipulation refers to an oligonucleotide that is provided as a reagent to detect a target potentially present in a sample of interest by hybridizing with the target.
  • a probe will comprise a label or a means by which a label can be attached, either before or subsequent to the hybridization reaction.
  • Suitable labels include, but are not limited to radioisotopes, fluorochromes, chemiluminescent compounds, dyes, and proteins, including enzymes.
  • a “primer” is an oligonucleotide, generally with a free 3'-OH group, that binds to a target potentially present in a sample of interest by hybridizing with the target, and thereafter promotes polymerization of a polynucleotide complementary to the target.
  • amplification processes of producing replicate copies of the same polynucleotide, such as PCR or gene cloning, are collectively referred to herein as "amplification” or “replication".
  • amplification processes of producing replicate copies of the same polynucleotide, such as PCR or gene cloning, are collectively referred to herein as "amplification” or “replication”.
  • single or double-stranded DNA may be replicated to form another DNA with the same sequence.
  • RNA may be replicated, for example, by and RNA-directed RNA polymerase, or by reverse-transcribing the DNA and then performing a PCR. In the latter case, the amplified copy of the RNA is a DNA with the identical sequence.
  • PCR polymerase chain reaction
  • PCR is a reaction in which replicate copies are made of a target polynucleotide using one or more primers, and a catalyst of polymerization, such as a reverse transcriptase or a DNA polymerase, and particularly a thermally stable polymerase enzyme.
  • a PCR involves reiteratively forming three steps: "annealing”, in which the temperature is adjusted such that oligonucleotide primers are permitted to form a duplex with the polynucleotide to be amplified; “elongating”, in which the temperature is adjusted such that oligonucleotides that have formed a duplex are elongated with a DNA polymerase, using the polynucleotide to which they have formed the duplex as a template; and “melting”, in which the temperature is adjusted such that the polynucleotide and elongated oligonucleotides dissociate. The cycle is then repeated until the desired amount of amplified polynucleotide is obtained.
  • Methods for PCR are taught in USP No. 4,683, 1 95 to Mullis and USP 4,683,202 to Mullis et al.
  • Elements within a gene include but are not limited to promoter regions, enhancer regions, repressor binding regions, transcription initiation sites, ribosome binding sites, translation initiation sites, protein encoding regions, introns and exons, and termination sites for transcription and translation.
  • An "antisense" copy of a particular polynucleotide refers to a complementary sequence that is capable of hydrogen bonding to the polynucleotide and can therefor, be capable of modulating expression of the polynucleotide. These are DNA, RNA or analogs thereof, including analogs having altered backbones, as described above.
  • the polynucleotide to which the antisense copy binds may be in single-stranded form or in double- stranded form.
  • operatively linked means that the DNA molecule is positioned relative to the necessary regulation sequences, e.g., a promoter or enhancer, such that the promoter will direct transcription of RNA off the DNA molecule in a stable or transient manner.
  • Vector means a self-replicating nucleic acid molecule that transfers an inserted nucleic acid molecule into and/or between host cells.
  • the term is intended to include vectors that function primarily for the replication of nucleic acid and expression vectors that function for transcription and/or translation of the DNA or RNA. Also intended are vectors that provide more than one of the above functions.
  • “Host cell” is intended to include any individual cell or cell culture that can be or have been recipients for vectors or the incorporation of exogenous nucleic acid molecules and/or proteins. It also is intended to include progeny of a single cell, and the progeny may not necessarily be completely identical (in morphology or in genomic or total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • an “antibody” is an immunoglobulin molecule capable of binding an antigen. As used herein, the term encompasses not only intact immunoglobulin molecules, but also anti-idiotypic antibodies, mutants, fragments, fusion proteins, humanized proteins and modifications of the immunoglobulin molecule that comprise an antigen recognition site of the required specificity.
  • An “antibody complex” is the combination of antibody (as defined above) and its binding partner or ligand.
  • a "suitable cell” for the purposes of this invention is one that includes but is not limited to a cell expressing the SFRP, e.g., a bone marrow cell, preferentially an hOB cell.
  • a “biological equivalent” of a nucleic acid molecule is defined herein as one possessing essential identity with the reference nucleic acid molecule.
  • a fragment of the reference nucleic acid molecule is one example of a biological equivalent.
  • a “biological equivalent” of an SFRP polypeptide or protein is one that retains the same characteristic as the reference protein or polypeptide. It also includes fragments of the reference protein or polypeptide.
  • the SFRP proteins and polypeptides also can be obtained by chemical synthesis using a commercially available automated peptide synthesizer such as those manufactured by Applied Biosystems, Inc., Model 430A or 431 A, Foster City, CA and the amino acid sequence provided in SEQ. ID NO 2.
  • the synthesized protein or polypeptide can be precipitated and further purified, for example by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • this invention also provides a process for chemically synthesizing the proteins of this invention by providing the sequence of the protein (e.g., SEQ. ID NO 2) and reagents, such as amino acids and enzymes and linking together the amino acids in the proper orientation and linear sequence.
  • the proteins and polypeptides can be obtained by well- known recombinant methods as described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual 2d ed. (Cold Spring Harbor Laboratory ( 1 989)) using, for example, the host cell and vector systems described and exemplified below.
  • This invention further provides a process for producing a SFRP, analog, mutein or fragment thereof, by growing a host cell containing a nucleic acid molecule encoding the desired protein, the nucleic acid being operatively linked to a promoter of RNA transcription.
  • the desired protein may be introduced into the host cell by use of a gene construct which contains a promoter and termination sequence for the nucleic acid sequence of the desired protein.
  • the host cell is grown under suitable conditions such that the nucleic acid is transcribed and translated into protein.
  • the protein is further purified.
  • the proteins of this invention also can be combined with various liquid phase carriers, such as sterile or aqueous solutions, pharmaceutically acceptable carriers, suspensions and emulsions.
  • liquid phase carriers such as sterile or aqueous solutions, pharmaceutically acceptable carriers, suspensions and emulsions.
  • non-aqueous solvents include propyl ethylene glycol, polyethylene glycol and vegetable oils.
  • the carriers also can include an adjuvant that is useful to nonspecifically augment a specific immune response.
  • suitable adjuvants include, but are not limited to Freund's Complete and Incomplete, mineral salts and polynucleotides.
  • SFRPs/SARPs may serve as tumor suppressors due to their ability to antagonize Wnt activity.
  • These proteins may also be utilized in tissue regeneration.
  • FrzB-1 stimulated ectopic chondrogenic activity in vivo, it could be used to accelerate fracture repair or the healing of joints after hip and knee replacement (patent application number WO 98/1 6641 A1 ).
  • SFRPs/SARPs appear to control apoptosis, these proteins could also be utilized to treat a variety of degenerative diseases including neurodegeneration, myodegeneration and osteodegeneration disorders.
  • compositions containing any of the above-mentioned proteins, muteins, fragments, antibodies, nucleic acid molecules encoding such proteins, muteins, antibodies or fragments thereof, as well as vectors and host cells that express such nucleic acid molecules, and an acceptable solid or liquid, carrier buffer, or diluent.
  • An effective amount of one or more active ingredient is used which sufficient to accomplish the desired regulatory effect on a bone-forming activity or apoptosis activity.
  • An effective amount can be determined by conventional dose-response curves for the desired activity.
  • compositions of the invention may comprise one or more additional active components and, preferably, include a pharmaceutically acceptable carrier.
  • the additional active component may be provided to work in combination with an active based on a one or more SFRPs, as described above.
  • the additional active is added since it works on the same disease or disorder as SFRPs but by a different mode of action from those actives based on SFRPs, or the additional active may work on other diseases or disorders present in a human or animal.
  • Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • pharmaceutically acceptable carrier refers to a carrier that does not cause an allergic reaction or other untoward effect in patients to whom it is administered.
  • suitable pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
  • Pharmaceutically acceptable carriers may further comprise minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of one or more of the active components of the composition.
  • auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of one or more of the active components of the composition.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in immunogenic compositions of the present invention is contemplated.
  • compositions also can be used for the preparation of medicaments for the diagnosis and treatment of pathologies associated neurodegenerative (i.e., Huntington's disease, Alzheimer's disease, spinal cord injuries), myodegerative (i.e., muscular dsytrophy, myasthenia gravis, myotonic myopathies) and osteodegenerative disorders (i.e., osteoporosis).
  • neurodegenerative i.e., Huntington's disease, Alzheimer's disease, spinal cord injuries
  • myodegerative i.e., muscular dsytrophy, myasthenia gravis, myotonic myopathies
  • osteodegenerative disorders i.e., osteoporosis
  • antibodies that binds all or a portion of an SFRP protein are employed in the composition to treat of any of the above diseases or disorders.
  • Polyclonal and monclonal antibodies can be prepared by conventional methods. Generally, an antibody is raised against an amino acid sequence (a) that is specific to a SFRP protein (or proteins) and (b) that is also more likely to be antigenic.
  • an amino acid sequence that is hydrophilic at one or more ends, preferably at both ends, is generally preferred for raising antibodies.
  • the hydrophilic amino acids are also basic (non-acidic).
  • Antigenicity can be measured by an increase in decrease in the amount of antibody that is produced when generating antibodies against an initial test sequence, which is specific an SFRP protein(s).
  • the antibody is raised against a sequence comprising at least 8 consecutive amino acids of an SFRP protein(s), and preferably a sequence comprising at least 10 consecutive amino acids of an SFRP protein(s).
  • the antibody is raised against amino acid sequence comprising about 1 5 to about 30 amino acids.
  • the antibody is raised against a sequence comprising at amino acids 21 7-231 of an SFRP protein of SEQ ID NO 2 or sequence variations thereof.
  • compositions of the present invention can be administered to an individual in need of facilitated neural, muscle cartilage and bone growth by numerous routes, including but not limited to intravenous, subcutaneous, intramuscular, intrathecal, intracranial and topical.
  • the composition may be administered directly to an organ or to organ cells by in vivo or ex vivo methods.
  • compositions may be in soluble or microparticular form, or may be incorporated into microspheres or microvesicles, including micelles and liposomes.
  • compositions described above provide the components for an assay to screen for agents and pharmaceutical compounds that are agonists or antagonists of a Wnt receptor in a suitable cell.
  • the SFRP polynucleotides of the invention will have utility as diagnostic agents or detecting genetic abnormalities associated with genes encoding SFRP or with one or more genes involved in the Wnt signaling pathway.
  • genetic abnormalities include point mutations, deletions, or insertions of nucleotides.
  • Any of several genetic screening procedures may be adapted for use with probes enabled by the present invention, including restriction fragment length polymorphism (RFLP) analysis, ligase chain reaction, or PCR. Mutations in this gene indicate increased risk of developmental abnormalities.
  • RFLP restriction fragment length polymorphism
  • the proteins and fragments thereof are useful in a cell-free and cellular in vitro assay system to screen for agents and pharmaceutical compounds which either inhibit or augment the Wnt-receptor pathway and apoptosis and to test possible therapies for disorders associated with this pathway, e.g., bone formation diseases, carcinogenesis, and cardiovascular diseases.
  • Embryogenesis also can be modulated.
  • Drug screening assays can be used to identify activators or inhibitors of the SFRP protein. For example, an increase in cartilage growth in the presence of a drug compared to SFRP alone may indicate activation of SFRP, while a decrease may indicate inhibition of the SFRP activity.
  • a variety of compounds may be screened using methods of the present invention. They include peptides, macromolecules, small molecules, chemicals and biological mixtures. Such compounds may be biological, synthetic, organic, or inorganic compounds.
  • suitable cells are used for preparing diagnostic assays, for the expression of SFPRs or for preparing nucleotide- based diagnostic kits.
  • the cells may be made or derived from yeast, bacteria fungi, or viruses.
  • the cells are hOB cells, in particular a novel immortalized pre-osteocytic cell line referred to as hOB- 01 -C1 -PS-09 cells (which are deposited with American Type Culture Collection in Manassas, Va. with the designation PTA-785), and osteoblast cells having the identifying characteristics of hOB-01 -C1 -PS-09 cells as well as osteoblast cells made therefrom, e.g. progeny.
  • Immortalized refers to a substantially continuous and permanently established cell culture with substantially unlimited cell division potential. That is, the cells can be cultured substantially indefinitely, i.e., for at least about 6 months under rapid conditions of growth, preferably much longer under slower growth conditions, and can be propagated rapidly and continually using routine cell culture techniques. Alternatively stated, the cells of the present invention can be cultured for at least about 100, 1 50 or 200 population doublings. These cells produce a complement of proteins characteristic of normal human osteoblastic cells and are capable of osteoblastic differentiation. They can be used in cell culture studies of osteoblastic cell sensitivity to various agents, such as hormones, cytokines, and growth factors, or in tissue therapy. These cells are a post-senescent subclone of hOB-01 -C1 cell line, as previously disclosed by Bodine et al 1 996 Endocrinology 1 37:4592-4604.
  • SFRPs are new drug targets for osteoporosis
  • certain embodiments relate to the expression of genes or nucleic acids that encode all or portion of at least one SFRP protein. Expression of such nucleic acids or genes in human osteoblast (hOB) cell lines correlates with accelerated cell death and apoptosis.
  • hOB- 01 C1 PS-09 cells of this invention are particularly useful over other hOB cells since the present"-09" cells are adult osteoblast cells.
  • these cells are osteocytic (i.e. mature cells) in comparison to other hOB cells which are often osteoblastic.
  • the hOB-01 -C1 -PS-09 cells express very low levels of FRP-1 /SARP-2 message.
  • the hOB-01 -C 1 - PS-09 cell line will be a unique in vitro model to study the effects of FRP- 1 /SARP-2 reintroduction and over-expression.
  • Another important feature of the hOB-01 -C1 -PS-09 cells is that they can be used for both transient and stable transfection studies.
  • the hOB-01 -C1 -PS-09 cells will be useful for establishing stable cell lines that over-express potential osteoporotic drug targets. Such stable cell lines will then be valuable for characterizing these drug targets, as well as for developing high throughput screens and assays to identify compounds that regulate them.
  • Example A Generation and Analysis of hOB cells
  • the hOB-01 -C1 cells are a conditionally-transformed cell line derived from adult human bone that faithfully exhibit a pre-osteocytic phenotype. These cells were transformed with a temperature-sensitive large T-antigen (tsA 209) and proliferate at the permissive temperature of 34°C when the T- antigen mutant is active; however, the cells stop dividing at the non- permissive temperature (_> 37°C) when the T-antigen mutant is inactive.
  • tsA 209 temperature-sensitive large T-antigen
  • _> 37°C the non- permissive temperature
  • the hOB-01 -C1 cells undergo crisis and senesce after 1 5-20 passages in culture. Thus, although often referred to as “immortal”, such cell lines are actually only "extended-life”. The hOB-01 -C1 cells also proliferate slowly in culture at 34°C with a doubling time of about once every 5 to 6 days. In order to overcome some of these draw-backs, the hOB-01 -C 1 -PS-09 cell line was established.
  • the hOB-01 -C1 -PS-09 cells were developed by passaging the parental hOB-01 -C1 cell line beyond the crisis point (i.e., passages 1 5-20) until proliferation resumed (passages 20-25). The post-senescent cells were then expanded in culture and sub-cloned. Clones were characterized using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis to measure the levels of expression of parathyroid hormone (PTH)-1 receptor mRNA. The hOB-01 -C1 -PS-09 cells were chosen for further characterization, since this clone expressed the highest level of PTH-1 receptor message at 39°C.
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • This cell line went through approximately 20-25 population doublings during the cloning and expansion procedure, and has subsequently been passaged over 50-times. These cell line can be passaged hundreds of times. Thus, the hOB-01 -C1 -PS-09 cells are truly an immortal cell line.
  • the hOB-01 -C1 -PS-09 cells Like the parental hOB-01 -C1 cell line, the hOB-01 -C1 -PS-09 cells fail to form monolayer cultures and leave spaces on the tissue culture dishes. The cells also appear to form cell-to-cell contacts through long cellular processes. From analysis by electron microscopy, the cells possess finger- like cellular projections that are reminiscent of pre-osteocytes, and these processes form gap junctions when they contact adjacent cells. As with the parental cell line, the hOB-01 -C 1 -PS-09 cells also express the tsA 209 large T-antigen as determined by immunocytochemistry.
  • the hOB-01 -C1 -PS-09 cells proliferate 2- to 3-times faster at the permissive temperature with a doubling time of once every 2-3 days (Figure 22A).
  • the hOB-01 -C1 -PS-09 cells stop dividing at the non-permissive temperature ( Figure 22A). This observation indicates that although the cells have passed through the crisis point and become immortal, they still require an active T- antigen for proliferation.
  • the hOB- 01 -C1 -PS-09 cells require inactivation of the T-antigen in order to exhibit an enhanced osteocytic phenotype.
  • Alkaline phosphatase and osteocalcin are two important markers of the osteocytic lineage. As shown in Figure 22B, the ability of vitamin D 3 -treatment to up-regulate alkaline phosphatase activity is enhanced about 4-fold when the cells are incubated at 39°C. Furthermore, as depicted in Figure 22C, vitamin D 3 is unable to induce osteocalcin secretion from the cells at 34°C.
  • the secosteroid up-regulates production of this bone- specific matrix protein 1 1 -fold when the cells are incubated at 39°C.
  • the basal levels of alkaline phosphatase expression and osteocalcin secretion by the hOB-01 -C1 -PS-09 cells are similar to the parental cell line.
  • the hOB- 01 -C1 -PS-09 cells resemble the parental hOB-01 -C1 cells and are therefore a reliable in vitro model to study human pre-osteocyte biology.
  • the hOB-01 -C1 -PS-09 cell line was selected for further characterization based on its high-level of PTH-1 receptor mRNA expression.
  • the hOB-01 -C1 -PS-09 cells also respond to additional bone-active agents: for example, glucocorticoids and
  • TGF transforming growth factor
  • HGF hepatocyte growth factor
  • osteocytes An important property of osteocytes is the ability to respond to mechanosensory stimulation, such as that which occurs during weight- bearing exercise.
  • One method to simulate this stimulatory effect in vitro is through the use of a Flexercell Strain Unit (Flexcell International, Hillsborough, NC).
  • Flexercell Strain Unit Flexible Cell International, Hillsborough, NC.
  • the hOB-01 - C1 -PS-09 cells were seeded onto BioFlex type I collagen coated 6-well tissue culture dishes and incubated at 34°C for 24 hr.
  • the cells were then pre- incubated in serum-free medium at either 34°C or 39°C for an additional 24 hr, and then subjected to a physiologically-relevant strain (3400 ⁇ E, 2 Hz, 7200 cycles) at 37°C using an FX-3000 Flexercell Strain Unit. After the strain-treatment, the cells were incubated for 4.5 hr, at which time the conditioned medium was collected and analyzed for the presence of nitric oxide (NO). It has been previously reported that in vitro mechanosensory stimulation or shear-stress of rodent and chick osteoblasts and osteocytes stimulates NO production.
  • NO nitric oxide
  • mechanosensory stimulation i.e., "Flex" of the hOB-01 -C1 -PS-09 cells enhances the production of NO by 10- to 1 8-fold. Consequently, these data suggest that this cell line will be a useful in vitro model to study the molecular mechanisms of mechanosensory stimulation. Additional experiments establish that the hOB-01 -C 1 -PS-09 cells can be used for both transient and stable transfection studies. This cell line can be transfected using the Tfx-20 lipofection reagent (Promega, Madison, Wl).
  • luciferase expression when the luciferase expression is normalized to ⁇ -galactosidase expression in order to control for transfection efficiency, the level of luciferase expression is 2- to 3-fold higher when the cells are incubated at 34°C. Since luciferase expression is under the control of the SV-40 promoter, this observation is consistent with the tsA 209 T-antigen being inactivated at 39°C. Consequently, since these cells are both immortal and capable of being transfected, they can be used to develop stable over-expressing cell lines in a human pre-osteocytic background.
  • the hOB SFRP gene fragment was identified using RADE (rapid analysis of differential expression) technology as described by Shiue 1 997
  • hOB cell lines hOB-03-C5, hOB-03-CE6 and hOB-01 -C1 ), representing three distinct stages of differentiation (proliferative, mature and preosteocytic, respectively) were used to isolate and identify SFRP.
  • the hOB cell lines were established and cultured as previously described (Bodine et al. 1 996 J. Bone Miner. Res. 1 1 : 806-81 9; Bodine et al. 1 996 Endocrinology 1 37: 4592-4604; Bodine et al. 1 997 J. Cell. Biochem. 65: 368-387).
  • the cell lines were seeded into 1 50 mm dishes at - 40,000 cells/cm 2 with growth medium [D- MEM/F-1 2 containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1 % (v/v) Penicillin-Streptomycin and 2 mM GlutaMAX-1 ] and incubated overnight at 34°C.
  • D- MEM/F-1 2 containing 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1 % (v/v) Penicillin-Streptomycin and 2 mM GlutaMAX-1 ] and incubated overnight at 34°C.
  • the medium was removed, the cells were rinsed with phosphate-buffered saline (PBS), 20 ml of serum-free medium was added to the dishes [phenol red-free D-MEM/F-1 2 (Gibco/BRL) containing 0.25 % (w/v) bovine serum albumin (BSA, Pentex crystallized, Bayer), 1 % (v/v) Penicillin-Streptomycin, 2 mM GlutaMAX-1 , 50 mM ascorbate-2-phosphate (Wako), and 10 nM menadione sodium bisulfite (vitamin K3)], and the dishes were incubated at 39°C for 24 hr.
  • PBS phosphate-buffered saline
  • RNA samples were then treated with PBS and total cellular RNA was isolated from the nontreated and treated cells using TRIzol according to the manufacturers instructions (GibcoBRL).
  • RADE was then performed with the isolated RNA samples as above; the regulated gene fragments were identified, cloned and sequenced. These experiments identified a total of 82 differentially expressed genes.
  • a BLAST (basic local alignment search tool) search of the public data bases was performed on the RADE-obtained gene fragments; one of the gene fragments was highly homologous to mouse SFRP-1 .
  • This gene fragment was identified during RADE using the following primer pair: 5'-AAGCTTTTTTTTTTTA-3' (HT1 1 A)3' end (reverse primer) and 5'-AAGCTTGATTGCC-3' (H-AP1 ) 5' end (forward primer), which sequences are SEQ ID NO 1 1 and SEQ ID NO 1 2, respectively.
  • the expression and regulation of the gene fragment having homology to mouse cDNA SFRP-1 was confirmed by Northern blot analysis.
  • FIG. 1 depicts a summary of the RADE results.
  • the hOB SFRP gene fragment (indicated by the arrows) was strongly up-regulated by PGE 2 in the proliferative-stage (hOB-03-C5) and maturation-stage (hOB-03-CE6) hOB cell lines and down-regulated by TGF- ⁇ 1 in the pre-osteocytic (hOB-01 - C1 ) cell line.
  • basal expression of this gene was dramatically increased in the pre-osteocytic cells, suggesting that hOB SFRP gene expression is linked to the osteoblast differentiation process.
  • Example 3 Sequence Analysis of the hOB SFRP Gene Fragment
  • the hOB SFRP gene fragment identified in Example 1 , above, containing 276 base pair (bp) was cloned, sequenced, and a further subjected to a BLAST search of the public databases. This search revealed that this gene was homologous to two other previously identified cDNAs. Sequence alignment indicated that the hOB SFRP gene fragment shared 77% sequence identity to the 3'-end of mouse SFRP-1 gene (GeneBankTM Accession #U88566; Rattner et al. 1 997 Proc. Natl. Acad. Sci. USA 94: 2859-2863).
  • the hOB SFRP gene fragment also exhibited significant homology (87%) to the 3'-end of a related bovine cDNA called frizzled- related protein A (FrzA, GeneBankTM Accession #U85945). Additionally, the hOB SFRP gene fragment was very homologous to at least three expressed sequence tags (ESTs), human clone TM010 (GeneBankTM Accession #U5471 5), human CA1 1 tumor suppresser (GeneBankTM Accession #U691 22) and a human infant brain EST (GeneBankTM Accession #H 1 6753, H 1 6861 ).
  • ESTs expressed sequence tags
  • human clone TM010 GeneBankTM Accession #U5471 5
  • human CA1 1 tumor suppresser GeneBankTM Accession #U691 22
  • a human infant brain EST GeneBankTM Accession #H 1 6753, H 1 6861 .
  • hOB cell lines were treated with PTH, PGE 2 , and TGF- ⁇ 1 ; RNA was then isolated for Northern hybridizations. The results are shown in Figures 2 through 5. The experiments were performed as follows. The hOB cell lines were seeded into 1 50 mm dishes and treated as described in Example 1 , except that polyA -l- RNA was isolated from total cellular RNA using Oligotex mRNA maxi kits as described by the manufacturer (Qiagen).
  • Northern blot analysis was performed using either the excised RADE hOB SFRP gene fragment, the cloned hOB SFRP gene fragment or the cloned full- length hOB SFRP cDNA as a 32 P-labeled probe (as described in Bodine et al. 1 996 J. Bone Miner. Res. 1 1 : 806-81 9, which is incorporated herein). Each of these probes detected a 4.4-4.6 kb message in the hOB cells.
  • hOB SFRP glyceraldehyde phosphate dehydrogenase
  • ⁇ -actin mRNA
  • PGE 2 glyceraldehyde phosphate dehydrogenase
  • Basal SFRP mRNA levels were then measured by TaqMan quantitative RT-PCR. When compared to the hOB-03-C5 cells, basal SFRP message levels increased about 4-fold in the hOB-03-CE6 cells and about 23-fold in the hOB-01 -C1 cells.
  • SFRP mRNA levels declined to about 0.5-fold in the hOB-05-T1 cells.
  • the pre- osteocyte appears to express the highest levels of hOB SFRP message.
  • Proliferative hOB-03-C5 cells were seeded into 1 50 mm dishes and treated with increasing concentrations of PGE 2 for 24 hr or with 100 nM PGE 2 for varying lengths of time as described in Example 1 .
  • PolyA + RNA Northern blot analysis was performed with the excised RADE hOB SFRP 276 bp gene fragment or a cloned 1 .1 kb hOB SRFP gene fragment as a 32 P- labeled probe.
  • hOB-01 -C1 cells were seeded into 100 mm dishes and treated for 24 hr with increasing concentrations of TGF- ⁇ 1 .
  • Total RNA was then isolated from the cells, and hOB SFRP mRNA was measured by TaqMan quantitative RT-PCR.
  • TGF- ⁇ 1 suppressed SFRP gene expression by approximately 70% in a dose-dependent manner with an IC 50 of about 4 pM.
  • IL interleukin
  • IL- 1 ⁇ interleukin
  • 9-cis-retinoic acid or all-trans- retinoic acid increases hOB SFRP mRNA levels.
  • TGF- ⁇ 1 treatment of various hOB cell lines with PTH, bone morphogenetic protein (BMP)-2, insulin-like growth factor (IGF)-I, 1 7 ⁇ - estradiol (1 7 ⁇ -E 2 ), vitamin D 3 (VD 3 ), dexamethasone (Dex), or fetal bovine serum (FBS) suppresses hOB SFRP message expression.
  • BMP bone morphogenetic protein
  • IGF insulin-like growth factor
  • VD 3 vitamin D 3
  • Dex dexamethasone
  • FBS fetal bovine serum
  • Example 6 Tissue Distribution of hOB SFRP
  • tissue distribution for the expression of the hOB SFRP gene multiple human tissue poly(A) + RNA Northern blots (obtained from Clonetech) were probed with the excised RADE hOB SFRP gene fragment as described in Example 4.
  • RADE fragment was used to probe the poly (A) + RNA Northern blots
  • a - 4.4 kb transcript was expressed by several tissues (Figure 6).
  • Figure 6 When these results were normalized to ⁇ -actin, SFRP expression was ranked as follows:
  • This expression pattern is similar to the human FRP-1 /SARP-2 gene (Finch et al. 1 997 Proc. Natl. Acad. Sci. USA 94: 6770-6775; Melkonyan et al. 1 997 Proc. Natl. Acad. Sci. USA 94: 13636-1 3641 ).
  • Example 7 Distribution of SFRP in Osteoblast Cell Lines
  • SaOS-2 human osteosarcoma osteoblast-like cells were obtained from the American Type-Culture Collection (ATCC) and were cultured at 37°C in McCoy's 5A Modified medium containing 10% FBS, 1 % (v/v) Penicillin-Streptomycin and 2 mM GlutaMAX-1 .
  • explant cultures of normal human osteoblasts (hOBs) were established from cancellous bone chips as previously described (Bodine et al. 1 996 J. Bone Miner. Res.
  • Example 8 Isolation of Full Length hOB SFRP cDNA.
  • RT-PCR was performed using 1 ⁇ g of total RNA, primers that spanned the coding region of hFRP-1 /SARP-2 (forward primer: 5'-GCTGGGGACTGCGCCTTTTGT-3' SEQ ID NO 1 3; reverse primer: 5'-CCTGCCCCCGGGAGAATCACTTA-3' SEQ ID NO 14), 35 cycles of PCR, and the Advantage-GC PCR kit (Clonetech) according to the manufacturer's instructions.
  • RT-PCR of total RNA isolated from hOB-03-C5 cells treated with PGE 2 identified a 2.2 kb cDNA which spanned from the 5'-region of the hFRP-1 /SARP-2 cDNA to the 276 bp RADE fragment at the 3'-end.
  • These cDNA fragments were cloned into either the pcDNA3.1 (Invitrogen) mammalian expression vector (1 .1 kb cDNA) or the TA (Invitrogen) cloning vector (2.2 kb cDNA) and sequenced.
  • Sequence analysis of the hOB SFRP 1 .1 kb SEQ. ID. NO.
  • hOB cells were seeded at 200,000 cells/well into 6-well dishes and incubated at 34°C. The next day, one set of plates were rinsed with PBS, trypsinized, and baseline cell number (and mean cell volume) was determined with a Coulter Multisizer as previously described in Bodine et al. 1 996 J. Bone Miner. Res. 1 1 : 806-81 9, which is incorporated herein by reference. The other set of plates was placed at the nonpermissive temperature of 39°C, and cell number was determined 6 days later (the medium was changed on day 3).
  • the hOB-03-C5 cells which are in the proliferative-stage of osteoblast differentiation, divided slowly at 39°C and cell number increased by 60 to 80% after 6 days; this rate of cell division was similar to explant cultures of normal hOB cells (Bodine et al. 1 996 Endocrinology 1 37: 4592-4604).
  • the maturation-stage hOB-03-CE6 cells stopped dividing at the non-permissive temperature and cell number remained constant, while the pre-osteocytic hOB-01 -C1 cells slowly died at 39°C such that fewer than 40% of the cells remained alive after 6 days.
  • overexpression of SARP-2 in MCF-7 breast cancer cells accelerated the rate of cell death.
  • basal SFRP-1 /FRP-1 /SARP- 2 mRNA expression dramatically increased in the pre-osteocyte hOB-01 -C1 cells when compared to the proliferative hOB-03-C5 and mature hOB-03-CE6 cell lines.
  • the 6-well plates were rinsed with PBS, placed in BSA-medium, and treated at 39°C in the absence or presence of either 100 nM PGE 2 (in order to up- regulate SFRP-1 /FRP-1 /SARP-2 steady-state mRNA levels; panels A & B), or 0.01 -1 .0 nM TGF- ⁇ 1 (in order to down-regulate SFRP-1 /FRP-1 /SARP-2 message levels; panel C).
  • Incubating cells in serum-free medium is a common method to induce apoptosis (Melkonyan et al. 1 997 Proc. Natl. Acad. Sci.
  • results are presented as either the % relative to the day 0 control (i.e., - 200,000 cells per well of a 6 well plate) or as the % relative to the vehicle treated control.
  • the results of this experiment indicate that co-treatment of the hOB cells with the antisense oligonucleotide to SARP-2 reversed the ability of PGE 2 to accelerate the rate of cell death, while co-treatment with the sense (control) oligonucleotide has no effect on this process.
  • co-treatment of the cells with PGE 2 and an anti-peptide antibody to SARP-2 blocked the ability of PGE 2 to induce hOB cell death.
  • Figure 1 3 shows the results of a cell viability experiment with the hOB-01 -C1 -PS-09 cells using the Coulter cell counter.
  • the cells were stably transfected with either an hOB SFRP cDNA (i.e., SFRP-1 /FRP-1 /SARP-2) mammalian expression plasmid or the empty vector (i.e., pcDNA3.1 , which is obtained from Invitrogen of Carlsbad, CA).
  • Standard cloning technigues were used (See Ausubel et al. 1 997 Short Protocols in M ⁇ olecular Biology, 3 rd edition, Wiley ⁇ New York ⁇ ). The results are presented as the % of the day 0 control cells.
  • Example 1 2 Effect of hOB SFRP on Wnt Activity
  • hOB-03-CE6 cells were treated with PGE 2 and the resulting cells probed with ⁇ -catenin monoclonal antibody.
  • ⁇ -catenin a signaling protein known as ⁇ -catenin (reviewed in Moon et al. 1 997 Cell 88: 725-728; Barth et al. 1 997 Curr. Opin. Cell Biol. 9: 683-690; and Nusse 1 997 Cell 89: 321 -323).
  • SFRP- 1 /FRP-1 /SARP-2 down-regulated ⁇ -catenin levels, which is consistent with an antagonism of Wnt activity (Melkonyan et al. 1 997 Proc. Natl. Acad. Sci. USA 94: 1 3636-1 3641 ). Therefore, hOB-03-CE6 cells were plated and treated with PGE 2 as described in Example 1 , except that total cellular protein was extracted and a Western blot analysis for ⁇ -catenin was performed using a monoclonal antibody to the protein (Transduction Laboratories) as previously described (Bodine et al.
  • Example 1 3 Use of hOB SFRP in a Screening Method for Anabolic Agents
  • a new screening paradigm for an anabolic bone agent using SFRP is designed. As outlined in Figure 1 7, this screening paradigm uses the hOB cells and SFRP-1 /FRP-1 /SARP-2 to identify compounds that are capable of preventing or slowing osteoblast cell death. Such compounds act by blocking the ability of SFRP-1 /FRP-1 /SARP-2 to accelerate hOB cell death. These compounds bind to SFRP-1 /FRP-1 /SARP-2 and prevent it from binding a Wnt protein, or they may bind to a Wnt and prevent it from binding to SFRP-1 /FRP-1 /SARP-2. If SFRP-1 /FRP-1 /SARP-2 has activities that are independent of Wnt-binding (e.g., binding to a cell surface receptor), then these compounds could also act by preventing this Wnt-independent function as well.
  • Wnt-binding e.g., binding to a cell surface receptor
  • the hOB cell line could be one that naturally expressed high basal levels of SFRP-1 /FRP-1 /SARP-2 (e.g., hOB-01 -C1 cells), that transiently or stably overexpressed SFRP-1 /FRP-1 /SARP-2 (e.g., hOB-01 -C1 - PS-09 cells), or that stably or naturally expressed SFRP-1 /FRP-1 /SARP-2 in a conditional manner (e.g., hOB-03-C5 cells treated with PGE 2 ).
  • SFRP-1 /FRP-1 /SARP-2 e.g., hOB-01 -C1 cells
  • SFRP-1 /FRP-1 /SARP-2 e.g., hOB-01 -C1 cells
  • SFRP-1 /FRP-1 /SARP-2 e.g., hOB-01 -C1 cells
  • SFRP-1 /FRP-1 /SARP-2 e
  • cell number e.g., MTT or MTS dye-conversion or CyQuant DNA flourescence
  • apoptosis e.g., DNA fragmentation or annexin V binding
  • CyQuant kits were purchased from Molecular Probes (Eugene, OR).
  • FIG. 1 An example of a high-throughput screening assay (HTS) for SFRP- 1 /FRP-1 /SARP-2 inhibitors is depicted in Figure 1 8.
  • HTS high-throughput screening assay
  • pcDNA3.1 empty vector
  • SFRP-1 /FRP-1 /SARP-2 SARP-2 #1
  • stable overexpressing hOB-01 -C1 -PS-09 cells were seeded at 5000 cells per well into 96-well plates using growth medium. After a brief 6 hr incubation at 34°C, the wells were rinsed with PBS and incubated in BSA-medium at 39°C for 3 days.
  • the wells were rinsed again with PBS and then assayed for DNA content using the CyQuant DNA fluorescence assay (Molecular Probes).
  • the SARP-2 overexpressing cells died faster at 39°C such that after 3 days, only 20-30% of the cells were still alive. In contrast, 50-60% of the empty vector cells survived the incubation.
  • AS antipeptide antisera
  • the pre-immune serum had no effect on the SARP-2 overexpressing cells, and neither the pre-immune nor the immune sera affected the empty vector expressing cells.
  • a compound that inhibited osteoblast/osteocyte apoptosis would conceivably be an anabolic bone agent by prolonging the lives of these cells and thereby either increasing the amount of bone matrix that is synthesized and mineralized and/or maintaining the integrity of the bone.
  • a compound that inhibited osteoblast/osteocyte apoptosis would conceivably be an anabolic bone agent by prolonging the lives of these cells and thereby either increasing the amount of bone matrix that is synthesized and mineralized and/or maintaining the integrity of the bone.
  • SFRP-1 /FRP-1 /SARP-2 affects the skeleton
  • mice were prepared (See Wattler et al. 1 999. BioTechniques 26: 1 1 50-1 1 60). Deleting the SFRP-1 /FRP-1 /SARP-2 gene from mice would be akin to inhibiting its function with a drug, and this process allows us to validate this gene/protein as a potential drug target for osteoporosis.
  • the SFRP-1 knock-out mice were generated by substituting exon 1 of the mouse SFRP-1 gene with a ⁇ - galactosidase reporter gene/neomycin drug resistance gene expression cassette.
  • Northern blot analysis of poly A + RNA isolated from either female of male kidneys (age 1 6-1 8 weeks) demonstrated high levels of SFRP-1 mRNA expression (4.4 kb) in the wild-type (WT) control mice, but a complete absence of gene expression in the knock-out (KO) mice.
  • micro computerized tomography was used to characterize the trabecular bone architecture of the distal femurs from male and female wild-type control ( + / + ) and knock-out (-/-) mice (for a review of this technique, see Genant et al. 1 999 Bone 25: 149- 1 52 and Odgaard 1 997 Bone 20: 31 5-328).
  • the -/- mice had 31 % more trabecular bone volume (BV/TV) and an 8% increase in trabecular thickness (Tb. Th.) when compared to the + / + control mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP00960097A 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein Withdrawn EP1212355A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39483299A 1999-09-13 1999-09-13
US394832 1999-09-13
PCT/US2000/025035 WO2001019855A2 (en) 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein

Publications (1)

Publication Number Publication Date
EP1212355A2 true EP1212355A2 (en) 2002-06-12

Family

ID=23560597

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00960097A Withdrawn EP1212355A2 (en) 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein

Country Status (11)

Country Link
EP (1) EP1212355A2 (zh)
JP (1) JP2003512304A (zh)
CN (2) CN102988957A (zh)
AU (1) AU7131200A (zh)
BR (1) BR0014183A (zh)
CA (1) CA2383360A1 (zh)
CZ (1) CZ2002903A3 (zh)
IL (1) IL148421A0 (zh)
MX (1) MXPA02002624A (zh)
NZ (1) NZ529560A (zh)
WO (1) WO2001019855A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101117644A (zh) 2000-02-29 2008-02-06 阿尔康公司 青光眼的诊断和治疗药物
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
WO2002005857A2 (en) * 2000-07-19 2002-01-24 Genzyme Corporation Phosphatonin-related gene and methods of use thereof
US7488710B2 (en) 2001-01-10 2009-02-10 The United States Of America As Represented By The Department Of Health And Human Services SFRP and peptide motifs that interact with SFRP and methods of their use
EP1222933A1 (en) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
GB0111004D0 (en) * 2001-05-04 2001-06-27 Univ Sheffield Screening method
WO2003042384A1 (fr) * 2001-11-15 2003-05-22 Kyowa Hakko Kogyo Co., Ltd. Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation
EP1913952B1 (en) * 2002-12-05 2011-03-09 The Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and uses thereof
WO2004090161A1 (en) * 2003-04-14 2004-10-21 Novartis Ag Gene expression associated with osteoblast differentiation
CN104726460A (zh) * 2013-12-22 2015-06-24 上海交通大学医学院 蛋白sFRP-5在治疗银屑病的药物中的应用
EP3187191B1 (en) * 2014-08-26 2020-04-08 NKMAX Co., Ltd. Antibody for recognizing specific motif of wls protein, and pharmaceutical composition containing same
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
CN110361541A (zh) * 2019-07-23 2019-10-22 上海交通大学医学院附属瑞金医院 sFRP2和PCPE1作为联合靶点在制备纤维化疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681701A (en) * 1993-07-12 1997-10-28 Mayo Foundation For Medical Education And Research Immortalized human fetal osteoblastic cells
US5716944A (en) * 1994-07-04 1998-02-10 Takeda Chemical Industries, Ltd. Phosphonic acid compounds, their production and use
WO1998016641A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Isolation and method of using tissue growth-inducing frzb protein
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0119855A2 *

Also Published As

Publication number Publication date
CN1387537A (zh) 2002-12-25
BR0014183A (pt) 2002-05-14
NZ529560A (en) 2005-05-27
CA2383360A1 (en) 2001-03-22
AU7131200A (en) 2001-04-17
JP2003512304A (ja) 2003-04-02
MXPA02002624A (es) 2002-07-30
CN102988957A (zh) 2013-03-27
WO2001019855A3 (en) 2002-01-24
CZ2002903A3 (cs) 2002-07-17
IL148421A0 (en) 2002-09-12
WO2001019855A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
Rittling et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro
AU2023204606A1 (en) Genetically modified cells, tissues, and organs for treating disease
AU2023202107A1 (en) mRNA combination therapy for the treatment of cancer
EP1212355A2 (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
US20060035849A1 (en) Methods and composition for modulating type I muscle formation using pgc-1 alpha
US20110020348A1 (en) Pharmaceutical compositions and methods using secreted frizzled related protein
US20090226463A1 (en) Novel method of modulating bone-related activity
JP2005502312A (ja) タンパク質およびそれをコードする核酸
US20070028314A1 (en) Bone and/or joint disease-associated genes
JP2004534518A (ja) タンパク質およびそれをコードする核酸
WO2006133457A2 (en) Bone morphogenetic variants, compositions and methods of treatment
AU726918B2 (en) TGFbeta signal transduction proteins, genes, and uses related thereto
EA007611B1 (ru) Белок, имеющий в своей структуре цистиновые узлы
US20080039416A1 (en) Methods for Treating Disease by Modulating an Osmotic Stress Pathway
US7098372B1 (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
AU2005201918B2 (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
US6586581B1 (en) Prolactin regulatory element binding protein and uses thereof
JP2002528067A (ja) オステオプロテゲリン様タンパク質をコードする核酸およびその使用方法
US7270968B2 (en) PTH analogs for renal osteodystrophy and related uses
JP2001505420A (ja) 肝臓アクチビン／インヒビンのヌクレオチド配列およびタンパク質配列ならびにそれらに基づく方法
Eldadah The Marfan syndrome: Studies on pathogenesis and molecular diagnosis
US20030064434A1 (en) Novel G Protein-coupled receptor, GAVE1
Fortin Regulation of pituitary gonadotropin synthesis and fertility by gonadotropin-releasing hormone and activin signaling
JP2003525610A (ja) 熱応答に関連する遺伝子ｇ１２ｌ
Ranger et al. NF-ATc is essential for

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020305

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

17Q First examination report despatched

Effective date: 20020912

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120403